Changes in smoking status among substance abusers: baseline characteristics and abstinence from alcohol and drugs at 12-month follow-up
Changes in smoking status among substance abusers: baseline characteristics and abstinence from alcohol and drugs at 12-month follow-up
复制标题
DOI：
10.1016/s0376-8716(02)00256-9
复制
发表时间：
2003-01-24
影响因子：
4.2
通讯作者：
Weisner, CM
中科院分区：
文献类型：
--
作者：
Kohn, CS;Tsoh, JY;Weisner, CM
在寻求药物滥用（SA）治疗的HMO人群中，研究了吸烟状态变化对12个月SA治疗结果的影响。在基线时进入研究的749名参与者中，649名（86.9%）在12个月随访时保留。在治疗开始时，395名参与者是吸烟者，254名是非吸烟者。在12个月随访时，395名基线吸烟者中有13%报告戒烟，254名基线不吸烟者中有12%报告开始/复吸。与那些仍然吸烟的人相比，那些戒烟的人被诊断为酒精依赖的可能性更小。与所有其他组相比，开始/恢复吸烟的患者在进入治疗时更有可能被诊断为酒精和药物依赖。戒烟者戒酒和戒除非法药物的总天数最多（调整后的M 310.6）或不吸烟者（调整后的M = 294.7），开始/恢复吸烟者最低（调整后的M = 246.6）或保持吸烟者（调整后的M = 258.2），即使在控制人口统计学因素后，（即年龄、收入）、心理社会（ASI精神病严重程度）和其他治疗特征（治疗停留时间，安非他酮处方）与12个月时禁欲天数相关。自我发起的戒烟似乎对SA治疗结果无害，并且可能是有益的。在进入SA治疗后开始/恢复吸烟可能是复发风险更大的个体的临床标志物。未来的研究可能需要测量所有参与者在所有时间点的吸烟状况，以包括使用物质的吸烟者的高风险群体。(C)2002爱思唯尔科学爱尔兰有限公司保留所有权利。
The impact of change in smoking status on 12-month substance abuse (SA) treatment outcomes was examined among an HMO population seeking SA treatment. Of the 749 participants who entered the study at baseline, 649 (86.9%) were retained at the 12-month follow-up. At treatment entry, 395 participants were smokers and 254 were nonsmokers. At 12-month follow-up, 13% of the 395 baseline smokers reported quitting smoking and 12% of the 254 baseline nonsmokers reported starting/relapsing to smoking. Those who quit smoking were less likely to be diagnosed as alcohol dependent compared to those that remained smokers. Those who started/resumed smoking were more likely to be diagnosed as both alcohol and drug dependent at treatment entry compared to all other groups. Total days abstinent from alcohol and illicit drugs was greatest for individuals who quit smoking (adjusted M 310.6) or who were nonsmokers (adjusted M = 294.7) and lowest for those who started/resumed smoking (adjusted M = 246.6) or remained smokers (adjusted M = 258.2), even after controlling for demographic (i.e. age, income), psychosocial (ASI psychiatric severity), and other treatment characteristics (length of treatment stay, prescribed bupropion) that were associated with days abstinent at 12 months. Self-initiated smoking cessation does not appear to be detrimental to SA treatment outcomes, and may be beneficial. Starting/resuming smoking after entering SA treatment may be a clinical marker for individuals at greater risk of relapse. Future studies may want to measure the smoking status of all participants at all time points in order to include this higher-risk group of substance using smokers. (C) 2002 Elsevier Science Ireland Ltd. All rights reserved.